HeartSciences Inc

HeartSciences Inc(HSCS)股票分析

$3.030

-0.087 (-2.88%)收盘时

Loading chart…
High
3.140
Open
3.090
VWAP
3.02
Vol
45.81K
Mkt Cap
3.47M
Low
2.900
Amount
138.51K
EV/EBITDA, TTM
0.27

HeartSciences Inc. is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. The Company has libraries of artificial intelligence-enhanced electrocardiography (AI-ECG) algorithms and is developing AI-ECG solutions to be made available on either a hardware- agnostic cloud-based platform or its proprietary MyoVista wavECG device, to help identify cardiovascular disease in any care setting worldwide in a manner to suit different care providers. Its first product candidate for FDA clearance, the MyoVista wavECG, or the MyoVista, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction, which has traditionally only been available through the use of cardiac imaging. The MyoVista also provides conventional ECG information in the same test. It delivers AI-ECG algorithms using existing ECG devices across a hospital or health system.

AI analysis of HeartSciences Inc (HSCS)

buy

Heart Test Laboratories Inc is a good buy right now due to its recent positive momentum, with a 5-day price change of +8.21% and a strong gross margin of 58.33%. The stock is currently priced at $3.03, and the recent investment of $1 million by Fortitude at a 22% premium shows strong market confidence. However, the main risk is the negative earnings per share (EPS) of -0.88 reported in the last quarter, indicating ongoing profitability challenges.

估值指标

The current forward P/E ratio for HeartSciences Inc (HSCS) is 0.00, compared to its 5-year average forward P/E of -1.19.

Forward P/E

Overvalued
5Y Average P/E
-1.19
Current P/E
0.00
高估
-0.26
低估
-2.13

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
1.19
Current EV/EBITDA
0.27
高估
6.55
低估
-4.16

Forward P/S

Fair
5Y Average P/S
188.96
Current P/S
4.46
高估
1099.72
低估
-721.80

Alphio AI Price Scenarios for HSCS

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%HSCS

$5.42

情景价格

B

Base

Base · 50%HSCS

$4.73

情景价格

B

Bear

Bear · 25%HSCS

$4.32

情景价格

事件时间线

2026-08-20 (ET)

08:00:00

Fortitude Reports Adjusted EBITDA of $8.5M

2026-08-19 (ET)

09:30:00

Fortitude Mining Acquires 411,522 Shares of HeartSciences for Approximately $1M

2026-08-04 (ET)

08:00:00

Fortitude Mining Completes Acquisition of 12.5 MW Digital Infrastructure in Nebraska

2026-07-30 (ET)

08:00:00

Fortitude Mining Signs Purchase Agreement with Bitmain for 9,000 Antminer Z15 Pro Units

2026-07-28 (ET)

08:01:00

Fortitude Mining Energizes New Facility in Nebraska

资讯

HSCS FAQ — answered by Alphio AI

HeartSciences Inc. is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. The Company has libraries of artificial intelligence-enhanced electrocardiography (AI-ECG) algorithms and is developing AI-ECG solutions to be made available on either a hardware- agnostic cloud-based platform or its proprietary MyoVista wavECG device, to help identify cardiovascular disease in any care setting worldwide in a manner to suit different care providers. Its first product candidate for FDA clearance, the MyoVista wavECG, or the MyoVista, is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction, which has traditionally only been available through the use of cardiac imaging. The MyoVista also provides conventional ECG information in the same test. It delivers AI-ECG algorithms using existing ECG devices across a hospital or health system. It operates in the Healthcare sector (ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUP industry).

Heart Test Laboratories Inc is a good buy right now due to its recent positive momentum, with a 5-day price change of +8.21% and a strong gross margin of 58.33%. The stock is currently priced at $3.03, and the recent investment of $1 million by Fortitude at a 22% premium shows strong market confidence. However, the main risk is the negative earnings per share (EPS) of -0.88 reported in the last quarter, indicating ongoing profitability challenges.

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

免费开始